Bristol Restructures To Cut Costs, Transform Into Next-Generation Biopharma
This article was originally published in The Pink Sheet Daily
Executive Summary
Plan to achieve $1.5 billion in cost reductions by 2010 includes a 10 percent net reduction in head count.
You may also be interested in...
Bristol Sells ConvaTec Wound Care For $4.1 Billion
Sale represents Bristol’s latest effort to sharpen its focus on drugs.
Bristol Sells ConvaTec Wound Care For $4.1 Billion
Sale represents Bristol’s latest effort to sharpen its focus on drugs.
Bristol-Myers Squibb Reports Strong Fourth Quarter Sales, But Gains Minimized By Write-Offs
Firm’s short-term investment portfolio dinged by shaky fourth-quarter securities market.